coi other public disclosures 2017 managed · crv_00006569 carl thummel professor and principal...

Reference Investigator Investigator's Title/Role Title of Research Project Business EntityNature of Financial Interest Approximate Dollar Value

CRV_00000931 Philip BernardAssociate Professor and Co‐Investigator GENETIC EPIDEMIOLOGY OF BREAST CANCER Bioclassifier Equity Interest

Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00001547 Agnes OstafinResearch Associate Professor and Principal Investigator RETRIEVABLE BLOOD OXYGEN CARRIER SYSTEM BRIDGE FUNDS

Nanoshell Company, LLC Equity Interest


CRV_00002616 Vicente Planelles Professor and Co‐InvestigatorAnalysis of Latent HIV‐1 Infection in Peripheral Blood Lymphocytes of Aviremic HIV‐1 Infected Patients N/A Intellectual Property


CRV_00002816 Anne BlaschkeAssociate Professor and Principal Investigator

PCR‐Based Identification of Pathogenic Organisms from Blood Culture and CSF N/A Intellectual Property


CRV_00002858 Gerald Krueger Professor and Co‐Investigator Abbott Fellowship 2014Abbott Pharmacutical

Income for Consulting/Education/Speaking $10,000‐19,999

CRV_00002886 Anne BlaschkeAssociate Professor and Principal Investigator PCR for the Diagnosis of Bloodstream Infection in the NICU N/A Intellectual Property


CRV_00002888 Carrie Byington Professor and Co‐Investigator PCR for the Diagnosis of Bloodstream Infection in the NICU N/ARoyalty Income from Intellectual Property $5,000‐9,999

CRV_00003061 Anne BlaschkeAssociate Professor and Co‐Investigator Epidemiology and Etiology of Hospitalized Pneumonia in Children N/A Intellectual Property


CRV_00003062 Carrie Byington Professor and Co‐Investigator Epidemiology and Etiology of Hospitalized Pneumonia in Children N/ARoyalty Income from Intellectual Property $5,000‐9,999

CRV_00003240 Alberto BosqueResearch Assistant Professor and Principal Investigator Reactivation of latent HIV through TLR signaling N/A Intellectual Property


CRV_00003514 Richard CawthonResearch Associate Professor and Co‐Investigator The Utah study of Fertility, Longevity and Aging N/A Intellectual Property


CRV_00003523 Christopher Peters Professor and Co‐Investigator Vanguard SSK 360 Revision Knee System Global Data Collection BiometRoyalty Income from Intellectual Property >$100,000

CRV_00003523 Christopher Peters Professor and Co‐Investigator Vanguard SSK 360 Revision Knee System Global Data Collection BiometIncome for Educational Courses $20,000‐39,999

CRV_00003785 Siam OottamasathienAssociate Professor and Principal Investigator Mechanisms for Bladder Inflammation and Fibrosis

Glycomira Therapeutics

Equity Interest/Intellectual Property



Real‐Time Multiplex PCR for Diagnosis of Bacterial and Viral Infections in Children N/A Intellectual Property


CRV_00003880 Carrie Byington Professor and Co‐InvestigatorReal‐Time Multiplex PCR for Diagnosis of Bacterial and Viral Infections in Children N/A

Royalty Income from Intellectual Property $5,000‐9,999

CRV_00004124 Edward Dudek Professor and Principal Investigator TARGETED INTERNEURON ABLATION AND EPILEPTOGENESIS Epitel



CRV_00004125 Edward Dudek Professor and Principal InvestigatorIVERMECTIN ACTIVATED HUMAN GLYCINE RECEPTOR SUPPRESSION OF PHARMACORESISTENT EPILEPSY Epitel



CRV_00004422 Paul LaStayo Professor and Co‐Investigator Reducing Falls with RENEW in Older Adults Who Have Fallen N/A Intellectual PropertyValue cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00004481 Bradley Katz Professor and Principal Investigator

Thin film spectacle coatings to reduce light sensitivity and headaches

in child and adolescent patients with migraine Axon Optics, LLC



CRV_00004729 Dan Kadrmas Professor and Co‐Investigator Multi‐Tracer PET Assessment of Primary Brain TumorsMultiFunctional Imaging, LLC



CRV_00004733 Christopher Peters Professor and Co‐Investigator A Clinical Evaluation of the Vangaurd XP Bicruciate Knee System BiometRoyalty Income from Intellectual Property >$100,000

CRV_00004733 Christopher Peters Professor and Co‐Investigator A Clinical Evaluation of the Vangaurd XP Bicruciate Knee System Biomet


CRV_00004997 Howard Colman Professor and Principal Investigator

Alliance A071101 >> A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein‐Peptide Complex‐96 (HSPPC‐96) (NSC #725085, Alliance IND# 15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectabl Hoffman La Roche

Income for Consulting/Advisory Board $5,000‐9,999

CRV_00005106 Michael Esplin Professor and Co‐InvestigatorGenomic and Proteomic Network for Preterm Birth Research: Case Control Study Sera Prognostics



CRV_00005108 Michael Esplin Professor and Co‐InvestigatorGenomics and Proteomics Network for Preterm Birth: Expression Profiling Study Sera Prognostics



CRV_00005110 Michael Esplin Professor and Co‐InvestigatorGenomics and Proteomics Network for Preterm Birth Research: Longitudinal Study Sera Prognostics



CRV_00005449 Roy BloebaumResearch Professor and Principal Investigator

PREVENTION OF BIOFILM RELATED INFECTIONS USING A NOVEL, BROAD SPECTRUM ANTIMICROBIAL COATING, CSA‐13, ON ORTHOPEDIC FIXATION PLATES N/A Intellectual Property


CRV_00005860 Stephane MeystreAssistant Professor and Principal Investigator

Automated Problem and Allergy Lists Enrichment Based on High Accuracy Information Extraction from the Electronic Health Record Clinacuity CEO/Intellectual Property


CRV_00005943 Greg Jones Faculty and Co‐investigatorAutomated Problem and Allergy Lists Enrichment Based on High Accuracy Information Extraction from the Electronic Health Record Clinacuity Equity Interest


CRV_00006229 Florian Solzbacher Professor and Co‐InvestigatorRevolutionizing Utah Array using Nanotechnology to Enhance Efficacy and Logevity

Blackrock Microsystems Income for Consulting >$100,000


Blackrock Microsystems



CRV_00006252 Manoranjan Misra Professor and Principal InvestigatorRapid Diagnosis of Tuberculosis at the Point of Care Using a Handheld Volatile Biomarker Sensor

NANOSYNTH MATERIALS AND SENSORS INC



CRV_00006267 Sung Wan Kim Professor and Principal InvestigatorDesign of Oncolytic Adenovirus Conjugated with Novel Polymer for Cancer Treatment N/A Intellectual Property


CRV_00006312 Siam OottamasathienAssociate Professor and Principal Investigator Treatment of Bladder Pain by Novel Glycosaminoglycan Derivatives

Glycomira Therapeutics Equity Interest


CRV_00006313 Glenn Prestwich Professor and Co‐Investigator Treatment of Bladder Pain by Novel Glycosaminoglycan DerivativesGlycomira Therapeutics



CRV_00006569 Carl Thummel Professor and Principal Investigator Regulation of Metabolism in Drosophila N/A Intellectual PropertyValue cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00006796 Glenn Prestwich Professor and Principal InvestigatorAnti‐Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis




CRV_00007427 Christopher PeltAssociate Professor and Principal Investigator

A Clinical Evaluation of the Vanguard XP Bicruciate Knee System Early Intraoperative & Candidacy Assessment Biomet


CRV_00007441 Eugene KholmovskiResearch Assistant Professor and Principal Investigator

Cardiac MRI Techniques for Atrial Fibrillation Research and Management N/A Intellectual Property


CRV_00007657 Christopher PeltAssociate Professor and Co‐Investigator A Clinical Evaluation of the Vanguard XP Bicruciate Knee System Biomet


CRV_00008094 Gerald Krueger Professor and Co‐Investigator

Efficacy of Ustekinumab (Anti‐IL‐12/23) followed by Abatacept (CTLA4‐Ig) for the Treatment of Psoriasis Vulgaris Protocol ITN059AI (Pause Study) Version 2.0 30SEP2013

Vascular Biologics Limited



Efficacy of Ustekinumab (Anti‐IL‐12/23) followed by Abatacept (CTLA4‐Ig) for the Treatment of Psoriasis Vulgaris Protocol ITN059AI (Pause Study) Version 2.0 30SEP2013 Pfizer



Efficacy of Ustekinumab (Anti‐IL‐12/23) followed by Abatacept (CTLA4‐Ig) for the Treatment of Psoriasis Vulgaris Protocol ITN059AI (Pause Study) Version 2.0 30SEP2013 Facilitate of IDE



Efficacy of Ustekinumab (Anti‐IL‐12/23) followed by Abatacept (CTLA4‐Ig) for the Treatment of Psoriasis Vulgaris Protocol ITN059AI (Pause Study) Version 2.0 30SEP2013 Amgen



Efficacy of Ustekinumab (Anti‐IL‐12/23) followed by Abatacept (CTLA4‐Ig) for the Treatment of Psoriasis Vulgaris Protocol ITN059AI (Pause Study) Version 2.0 30SEP2013

Abbott Pharmacutical



Efficacy of Ustekinumab (Anti‐IL‐12/23) followed by Abatacept (CTLA4‐Ig) for the Treatment of Psoriasis Vulgaris Protocol ITN059AI (Pause Study) Version 2.0 30SEP2013 Centocor



Efficacy of Ustekinumab (Anti‐IL‐12/23) followed by Abatacept (CTLA4‐Ig) for the Treatment of Psoriasis Vulgaris Protocol ITN059AI (Pause Study) Version 2.0 30SEP2013 Novartis


CRV_00008243 Balamurali Ambati Professor and Principal Investigator Intraceptor Interference of VEGF in Ocular Angiogenesis N/A Intellectual PropertyValue cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00008445 David Krizaj Professor and Principal Investigator The role of mechanosensation in the vertebrate retina Asha Vision, LLC



CRV_00008593 James BeckAdjunct Assistant Professor and Co‐Investigator

Safety Study of Percutaneous Osseointegrated Iplants for Prosthetic Attachment‐Stuart IPA N/A Intellectual Property


CRV_00008722 Paul LaStayo Professor and Co‐InvestigatorThe effect of a novel nutritional and contractile countermeasure on the regulation of protein synthesis in older adults with hip fracture N/A Intellectual Property $10,000‐19,999

CRV_00008800 Howard Colman Professor and Co‐Investigator

GSK EGF111767: An Open‐Label, Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination with other Anticancer Treatment in Patients with Solid Tumors

Hoffman La Roche/Genetech


CRV_00009194 Sancy Leachman Adjunct Professor and Co‐Investigator Molecular Classifications of Cancer Myriad Genetics Income for Consulting $5,000‐9,999

CRV_00009230 Sancy Leachman Adjunct Professor and Co‐Investigator Cancer Genetics Study Myriad Genetics Income for Consulting $5,000‐9,999

CRV_00009291 Greg Jones Faculty and Co‐investigator

Proposal to Create IPEnclave, a Machine Intelligence‐based system for Innovative

Organizations to Assess, Manage and License Intellectual Property

University Innovation Services, LLC



CRV_00009477 Howard ColmanAssociate Professor and Co‐Investigator

A Phase 1b/2 Study of Repeat rAdiation, Minocycline, and Bevacizumab

in patients with recurrent gliOma (RAMBO)Hoffman La Roche/Genetech


CRV_00009676 Kathryn PetersonAssociate Professor (Clinical) and Co‐Investigator Radioimaging Eosinophilia Immviz Intellectual Property


CRV_00009961 Greg Jones Faculty and Co‐investigatorAutomated Dynamic Lists for Efficient Electronic Health Record Management Clinacuity Equity Interest


CRV_00010313 Meghan ZornPhysician Assistant and Co‐Investigator

PRIDE‐HD: A Phase 2, Dose‐Finding, Randomized, Parallel‐Group, Double‐Blind, Placebo‐Controlled Study Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice‐Daily versus Placebo for Symptomatic Treatment in Patients w Teva


CRV_00010340 David TurokAssistant Professor and Principal Investigator

Patient discomfort with a novel suction based cervical retractor compared to the traditional cervical tenaculum Bioceptive Inc. Equity Interest


CRV_00010652 Anne BlaschkeAssociate Professor and Principal Investigator ITI Subaward Meningitis SBIR N/A Intellectual Property


CRV_00010719 David TurokAssistant Professor and Principal Investigator

Patient discomfort with a novel suction based cervical retractor compared to the traditional cervical tenaculum Bioceptive Inc. Equity Interest


CRV_00010929 Dan Kadrmas Professor and Principal Investigator Multi‐Tracer PET Tumor ImagingMultiFunctional Imaging, LLC



CRV_00010936 Edward Di Bella Professor and Co‐Investigator Multi‐Tracer PET Tumor Imaging N/A Intellectual Property $10,000‐19,999

CRV_00010944 Christopher PeltAssociate Professor and Co‐Investigator Vanguard SSK 360 Revision Knee System Global Data Collection Biomet


CRV_00011371 Peter Stevens Professor and Principal Investigator Limb Deformity Registry N/ARoyalty Income from Intellectual Property >$100,000

CRV_00011843 Sunil Sharma Professor and Co‐Investigator(PQB‐2) "Driver" vs. "passenger" epigenetic events in Ewing sarcome

Salarius Pharmaceuticals



CRV_00012309 Christopher PetersAssociate Professor and Co‐Investigator

Randomized Controlled Clinical Outcomes of the Vanguard XP Bicruciate Knee System: GK9b Biomet Income for Consulting $20,000‐39,999

CRV_00012310 Christopher PeltAssociate Professor and Co‐Investigator

Randomized Controlled Clinical Outcomes of the Vanguard XP Bicruciate Knee System: GK9b Biomet


CRV_00012320 Kenneth AstonAssistant Professor and Co‐Investigator Epigenetics of the Paternal Contribution to Pediatric Cancer Risk N/A Intellectual Property


CRV_00012418 James HotalingAssistant Professor and Co‐Investigator

Preliminary investigation of erectile function using a non‐invasive measurement device Andro360 Equity Interest


CRV_00012759 John FangProfessor (Clinical) and Co‐Investigator

Placement of Veritract Smart Feeding Tube: Healthy Human Volunteer Study Veritract



CRV_00012809 Dan Kadrmas Professor and Co‐InvestigatorMulti‐Tracer PET Prediction and Assessment of Response to Gemcitabine‐plus‐Abraxane in Pancreatic Cancer Patients

MultiFunctional Imaging, LLC



CRV_00012918 Gerald Krueger Professor and Principal Investigator Immune Tolerance NetworkJanssen Pharmaceutical Inc


CRV_00012999 Anne BlaschkeAssociate Professor and Co‐Investigator

Mortality and Morbidity Associated with Respiratory Viral Infection in Infants following Congenital Heart Disease Surgical Repair N/A Intellectual Property


CRV_00013186 Sunil Sharma Professor and Principal Investigator LSD2 InhibitorsBeta Cat Pharmaceuticals Equity Interest


CRV_00013187 Sunil Sharma Professor and Principal InvestigatorProtein targets of Histone‐lysine N‐methyltransferase Enhancer of zeste homolog 2 (EZH2) related targets

Beta Cat Pharmaceuticals Equity Interest


CRV_00013188 Sunil Sharma Professor and Principal Investigator

Protein targets of Gli, a protein originally isolated in human glioblastoma and an effector of Hedgehog (Hh) signaling (GLI) related targets

Beta Cat Pharmaceuticals Equity Interest


CRV_00013409 Luke SimonPost Doctoral Fellow and Co‐Investigator

Micro‐Electrophoresis: A novel approach to select mature and genetically fit sperm N/A Intellectual Property


CRV_00013410 Douglas Carrell Professor and Principal InvestigatorMicro‐Electrophoresis: A novel approach to select mature and genetically fit sperm N/A Intellectual Property


CRV_00013504 Prashant TathireddyResearch Associate Professor and Co‐Investigator

Plasma‐assisted atomic layer deposition of alumina and Parylene‐C bi‐layer encapsulation

Blackrock Microsystems Employment $20,000‐39,999

CRV_00013505 Florian Solzbacher Professor and Principal Investigator Plasma‐assisted atomic layer deposition of alumina and Parylene‐C bi‐layer encapsulation

Blackrock Microsystems Income for Consulting >$100,000

CRV_00013505 Florian Solzbacher Professor and Principal Investigator Plasma‐assisted atomic layer deposition of alumina and Parylene‐C bi‐layer encapsulation




CRV_00013517 Loren Rieth Faculty and Co‐investigatorPlasma‐assisted atomic layer deposition of alumina and Parylene‐C bi‐layer encapsulation


CRV_00013808 ALAN MORRIS Professor and Co‐Investigator Cardiac Image Analysis for Atrial Fibrillation Marrek, Inc Equity InterestValue cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00013929 Michael Kay Professor and Principal Investigator D‐PEPTIDE INHIBITORS OF HIV‐1 ENTRY Navigen



CRV_00013955 Anne BlaschkeAssociate Professor and Co‐Investigator Molecular Classification of Pediatric Cancer N/A Intellectual Property



PARAPNEUMONIC EMPYEMA: USE OF MOLECULAR METHODS TO IDENTIFY PATHOGENS AND OUTCOME N/A Intellectual Property


CRV_00013963 Anne BlaschkeAssociate Professor and Co‐Investigator Molecular Evaluation of Pediatric Joint Fluid N/A Intellectual Property


CRV_00014023 Gerald Krueger Professor and Co‐Investigator Vascular Inflammation in Psoriasis Extension (VIP‐E) TrialAbbott Pharmacutical


CRV_00014102 Dana CarrollDistinguished Professor and Principal Investigator Optimizing Genome Engineering with Targetable Nucleases N/A Intellectual Property


CRV_00014212 Debra EckertResearch Associate Professor and Co‐Investigator D‐PEPTIDE INHIBITORS OF HIV‐1 ENTRY Navigen Income for Consulting $10,000‐19,999

CRV_00014212 Debra EckertResearch Associate Professor and Co‐Investigator D‐PEPTIDE INHIBITORS OF HIV‐1 ENTRY Navigen



CRV_00014290 Agnes OstafinResearch Associate Professor and Principal Investigator

Haptoglobin Treatment to Reduce Complication of Sickle Cell Disease

Nanoshell Company, LLC Equity Interest


CRV_00014486 Christopher PetersAssociate Professor and Principal Investigator

Clinical and Biomechanical Outcomes Following Total Knee Arthroplasty Biomet


CRV_00014487 Christopher PeltAssociate Professor and Principal Investigator

Clinical and Biomechanical Outcomes Following Total Knee Arthroplasty Biomet


CRV_00014527 cheryl wrightAssociate Professor and Principal Investigator SketchUp Workshop Program Evaluation N/A Intellectual Property


CRV_00014528 Scott WrightAssociate Professor and Co‐Investigator SketchUp Workshop Program Evaluation NeuroVersity



CRV_00014697 James HotalingAssociate Professor and Principal Investigator StreamDx N/A Intellectual Property


CRV_00014779 Stephane MeystreAssistant Professor and Principal Investigator

Automated Dynamic Lists for Efficient Electronic Health Record Management Clinacuity CEO/Intellectual Property


CRV_00015271 David ShprecherAdjunct Associate Professor and Principal Investigator

A Phase 2, Dose‐Finding, Randomized, Parallel‐Group, Double‐Blind, Placebo‐Controlled Study, Evaluating the Safety and Efficacy of Pridopidine Teva Neuroscience Income for Consulting $10,000‐19,999


Vascular Inflammation in Psoriasis Trial (VIP) Protocol #814278

(A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease) Abbvie

Income for Consulting/Education/Speaking/Expert Witness $40,000‐59,999

CRV_00015946 jiyuan YangResearch Professor and Co‐investigator

Backbone Degradable Polymer‐Drug Conjugates for the Treatment of Ovarian Cancer TheraTarget Employment $20,000‐39,999

CRV_00015946 jiyuan YangResearch Professor and Co‐investigator

Backbone Degradable Polymer‐Drug Conjugates for the Treatment of Ovarian Cancer TheraTarget Intellectual Property


CRV_00015955 Michael Deininger Professor and Principal InvestigatorOHSU IIT Incyte 10262>>Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CS3FR Incyte


CRV_00015969 Dan Kadrmas Professor and Principal InvestigatorMulti‐Tracer PET/CT Imaging of Gemcitabine Response in Pancreatic Cancer

MultiFunctional Imaging, LLC



CRV_00016089 Flory NkoyResearch Assistant Professor and Principal Investigator

Organizational Factors Associated with Improved Inpatient Pediatric Asthma Care N/A Intellectual Property


CRV_00016090 Bernhard FasslAssistant Professor (Clinical) and Co‐Investigator



CRV_00016091 Bryan StoneProfessor (Clinical) and Co‐Investigator



CRV_00016121 Matthew ConverseGraduate Assistant and Co‐Investigator

Validation study of urine flow rate monitoring with novel device: StreamDx. Stream Dx



CRV_00016689 John Fang(Clinical) Professor and Co‐Investigator

Placement of Veritract Smart Feeding Tube: Healthy Human Volunteer Study Veritract



CRV_00017107 James MartinAssociate Professor and Principal Investigator

Active Desk: A Novel Invention for Improving Health in the Workplace N/A Intellectual Property


CRV_00017534 David TurokAssociate Professor (Clinical) and Princial Investigator

(TRIBE) Tracking IUD Bleeding Experiences: An evaluation of bleeding profiles in new intrauterine device users

Teva Women's Health

Employment/Advisory Board $5,000‐9,999

CRV_00017632 Philipp TausskyAssociate Professor and Principal Investigator

Prospective Study on Embolization of Intracranial Aneurysms with Pipeline Embolization Device (PREMIER) Covidien Income for Consulting $40,000‐59,999


BTTC 12‐01: A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangioenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab

Hoffman La Roche/Genetech Income for Consulting $5,000‐9,999

CRV_00017695 Howard Colman Professor and Principal Investigator

BTTC12‐01>> A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab

Hoffman La Roche/Genetech Income for Consulting $5,000‐9,999

CRV_00017740 Roger FreedmanProfessor (Clinical) and Principal Investigator Adapt Response Clinical Study Medtronic

Income for Consulting/Safety Monitory Committee $5,000‐9,999

CRV_00018036 Roger FreedmanProfessor (Clinical) and Principal Investigator AdaptResponse Medtronic


CRV_00018275 John Kircher Professor and Principal InvestigatorValidation of the Ocular‐motor Deception Test for Identifying Drug Use Violations Converus



CRV_00018821 Raminder Nirula Professor and Principal Investigator Patient Driven Surgical Discharge Process Improvement N/A Intellectual PropertyValue cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00019133 Gerald Krueger Professor and Co‐InvestigatorA Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics

Janssen Pharmaceutical Inc



An Evaluation of Bleeding Profiles in New Users of the Copper T380 IUD

Teva Women's Health


CRV_00019665 Dan Woltz Professor and Co‐InvestigatorValidation of the Ocular‐motor Deception Test for Identifying Drug Use Violations Converus




The Copper T380A IUD vs. Oral Levonorgestrel for Emergency Contraception

Teva Women's Health


CRV_00021028 Carl Wittwer Professor and Co‐InvestigatorMulti‐Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics N/A



CRV_00021164 Anne BlaschkeAssociate Professor and Principal Investigator Procalcitonin in Pediatric Pneumonia N/A Intellectual Property


CRV_00021190 Carol Bruggers Professor and Principal Investigator

Prototype video game of incentive‐based physical exercise for adolescent cancer patients (PE GAME): directly coupling physical exercise, via visualization and active participation,

to an empowerment of fighting cancer N/A Intellectual PropertyValue cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00021268 Howard Colman Professor and Principal InvestigatorDF/HCC 14‐477>>Phase II Study of Pembrolizumab (MK‐3475) With and Without Bevacizumab for Recurrent Glioblastoma



CRV_00021288 Anne Cook Professor and Co‐InvestigatorValidation of the Ocular‐motor Deception Test for Identifying Drug Use Violations Converus



CRV_00021451 Sunil Sharma Professor and Principal Investigator Preclinical Development of HCI‐2577 for Ewing's SarcomaSalarius Pharmaceuticals



CRV_00021570 Peter Stevens Professor and Principal InvestigatorCorrection of angular deformities due to focal fibrocartilaginous dysplasia using guided growth.

Orthopediatrics, Inc.

Royalty Income from Intellectual Property >$100,000

CRV_00021570 Peter Stevens Professor and Principal InvestigatorCorrection of angular deformities due to focal fibrocartilaginous dysplasia using guided growth.

Orthopediatrics, Inc.


CRV_00021750 Paul Bernstein Professor and Principal Investigator Macular Pigment Measurements in Eye & Other Tissues N/A Intellectual PropertyValue cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00022076 Jayant AgarwalAssociate Professor and Co‐Investigator

Pre‐Screening and Screening to identify the VA (and/or military) population that meets medical criteria for advanced prosthetic devices DJO Surgical Income for Consulting $10,000‐19,999


Pre‐Screening and Screening to identify the VA (and/or military) population that meets medical criteria for advanced prosthetic devices N/A Intellectual Property



Pre‐Screening and Screening to identify the VA (and/or military) population that meets medical criteria for advanced prosthetic devices N/A Intellectual Property



FilmArray Direct: Rapid Diagnosis of Antimicrobial‐Resistant Pathogens from Blood N/A Intellectual Property


CRV_00022451 James BarrettAssistant Professor (Clinical) and Co‐Investigator Patient Driven Surgical Discharge Process Improvement ProMD



CRV_00022546 Greg Jones Faculty and Co‐investigatorClinical Text Automatic De‐Identification to Support Large Scale Data Reuse and Sharing Clinacuity



CRV_00022632 Philipp TausskyAssociate Professor and Co‐Investigator

Outcomes of Pipeline Embolization Device for Intracranial Aneurysms Covidien Income for Consulting $60,000‐79.999


PROSPECTIVE STUDY ON EMBOLIZATION OF INTRACRANIAL ANEURYSMS WITH PIPELINE EMBOLIZATION DEVICE Covidien Income for Consulting $60,000‐79.999

CRV_00023217 Michael Kay Professor and Principal Investigator Protease‐Resistant D‐peptide Inhibitors of Ebola Entry Navigen



CRV_00023414 Michael Deininger Professor and Principal Investigator Medical College of Wisconsin>>The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST study) Novartis Income for Consulting $10,000‐19,999

CRV_00023414 Michael Deininger Professor and Principal Investigator Medical College of Wisconsin>>The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST study) Pfizer


CRV_00023414 Michael Deininger Professor and Principal Investigator Medical College of Wisconsin>>The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST study)

Bristol‐Myers Squibb Income for Consulting $5,000‐9,999

CRV_00023748 Michael Kay Professor and Principal InvestigatorHighly specific anti‐toxin therapies for severe bacterial gut infections Navigen Equity Interest


CRV_00023765 cheryl wrightAssociate Professor and Co‐Investigator

The Evaluation of a Peer‐Teaching Technology Education Program for Youth on the Autism Spectrum NeuroVersity




A PHASE 4, MULTICENTER, RANDOMIZED, PLACEBO‐CONTROLLED, DOUBLE‐BLIND, STUDY OF THE EFFICACY AND SAFETY OF APREMILAST (CC‐10004), IN SUBJECTS WITH MODERATE PLAQUE PSORIASIS Celgene



RAPID EC – RCT Assessing Pregnancy with Intrauterine Devices for Emergency Contraception

Teva Women's Health


CRV_00024243 Michael Deininger Professor and Principal Investigator

Avillion AV001>>A Multicenter Phase 3, Randomized, Open‐Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Novartis Income for Consulting $10,000‐19,999


Avillion AV001>>A Multicenter Phase 3, Randomized, Open‐Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Pfizer Income for Consulting $5,000‐9,999

CRV_00024284 David TurokAssociate Professor (Clinical) and Faculty Sponsor

Intent to receive a post‐partum contraceptive implant or IUD, continuation rates, and patient satisfaction

Teva Women's Health


CRV_00024422 Michael Kay Professor and Principal Investigator

RAPID: Optimizing experimental approaches to Ebola membrane fusion inhibitor peptide design through high‐throughput biomolecular simulation workflows on Blue Waters Navigen Equity Interest



Safety Study of Percutaneous Osseointegrated Implants for Prosthetic Attachment DJO Surgical Income for Consulting $10,000‐19,999


Safety Study of Percutaneous Osseointegrated Implants for Prosthetic Attachment DJO Surgical Intellectual Property



Safety Study of Percutaneous Osseointegrated Implants for Prosthetic Attachment N/A Intellectual Property



Highly Effective Reversible Contraceptive Initiative—Salt Lake (HER‐SLC)

Teva Women's Health


CRV_00025488 James BeckAdjunct Associate Professor and Principal Investigator

Microbiome and Innate Immunity with Percutaneous Osseointegrated Prostheses N/A Intellectual Property





CRV_00025491 Sujeevini JeyapalinaAdjunct Assistant Professor and Co‐Investigator



CRV_00026093 Allison PayneResearch Associate Professor and Principal Investigator

Safety and Efficacy of Magnetic Resonance Guided High Intensity Focused Ultrasound Ablation of Renal Sympathetic Arteries N/A Intellectual Property


CRV_00026206 jiyuan YangResearch Professor and Co‐investigator Drug‐Free Macromolecular Therapeutics N/A Intellectual Property


CRV_00026207 Paul Shami Professor and Co‐Investigator Drug‐Free Macromolecular Therapeutics Bastion Biologics Equity InterestValue cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00026247 Jindrich KopecekDistinguished Professor and Principal Investigator Drug‐Free Macromolecular Therapeutics N/A Intellectual Property


CRV_00027452 Luke SimonPost Doctoral Fellow and Co‐Investigator

A comparative analysis of sperm preparation methods to isolate genetically fit sperm N/A Intellectual Property $20,000‐39,999

CRV_00027721 Tibor KovacsovicsProfessor (Clinical) and Principal Investigator

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma Celgene


CRV_00028441 Howard Colman Professor and Co‐InvestigatorNRG/ECOG/ACRIN/NCI EAY131 (CIRB) >> Molecular Analysis for Therapy Choice (MATCH)



CRV_00030218 Carl Wittwer Professor and Co‐InvestigatorDevelopment of a rapid genetic test for positive sample identification. N/A Intellectual Property


CRV_00030577 Carl Wittwer Professor and Co‐InvestigatorMulti‐Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics N/A Intellectual Property



Evaluation of Estimated Patient Outcomes with access to Rapid Molecular‐Based Diagnostic Testing for Meningitis/Encephalitis ‐‐ BioFire Study # DX‐SDY‐022668 N/A Intellectual Property



Alliance/ECOG‐ACRIN E1910 (CIRB)>>A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR‐ABL‐negative B lineage Acute Lymphoblastic Leukemia in Adults Amgen Income for Consulting $10,000‐19,999

CRV_00031094 Howard Colman Professor and Co‐InvestigatorALLIANCE A071401>> Phase II Trial Of SMO/AKT/NF2 Inhibitors In Progressive Meningiomas With SMO/AKT/NF2 Mutations



CRV_00032369 Luming ZhouResearch Associate and Co‐Investigator

Development of a rapid genetic test for positive sample identification. N/A Intellectual Property


CRV_00032392 Roger FreedmanProfessor (Clinical) and Principal Investigator

Collection of ElectroMagnetic Interference

Signals Induced by an Electrosurgery Device

in Patients with ICDs or CRT‐Ds Medtronic


CRV_00032407 Peter Stevens Professor and Principal InvestigatorA Comparison of Two Surgical Methods of Management for Perthes Disease Orthofix, Inc Income for Consulting $10,000‐19,999

CRV_00032407 Peter Stevens Professor and Principal InvestigatorA Comparison of Two Surgical Methods of Management for Perthes Disease Orthofix, Inc

Royalty Income from Intellectual Property $60,000‐79.999

CRV_00033059 Loren Rieth Faculty and Co‐investigator

Can an array of micro‐electrodes implanted in a human nerve record neural signals and provide sensory feedback useful for controlling a prosthetic device?


CRV_00033175 Sujeevini JeyapalinaAdjunct Associate Professor and Principal Investigator



CRV_00033186 Ken Johnson Professor and Co‐InvestigatorEvaluation of Information Displays‐ A Paper, Computer and Simulator Based Study

Applied Medical Visualizations Equity Interest


CRV_00033188 Noah SyroidResearch Associate and Principal Investigator

Evaluation of Information Displays‐ A Paper, Computer and Simulator Based Study

Applied Medical Visualizations



CRV_00033347 Manoranjan Misra Professor and Principal Investigator TB Sensor Assessment N/A Intellectual PropertyValue cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00033348 Swomitra MohantyAssistant Professor and Co‐Investigator TB Sensor Assessment N/A Intellectual Property


CRV_00033371 Djordje AtanackovicAssociate Professor and Co‐Investigator

Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients

Millennium Pharmaceuticals



Evaluation of Estimated Patient Outcomes with access to Rapid Molecular‐Based Diagnostic Testing for Meningitis/Encephalitis N/A Intellectual Property


CRV_00034322 Sunil SharmaAdjunct Professor and Principal Investigator

(PQB‐2) â Driverâ vs. âpassengerâ epigene c events in Ewing sarcoma N/A



CRV_00034367 Joel Cooper Faculty and Principal Investigator Measuring Cognitive Distraction on the Road Red Scientific Employment $5,000‐9,999

CRV_00035192 Ravi RanjanAssociate Professor and Co‐Investigator Quadripolar Pacing Post Approval Study (QUAD PAS) St. Jude Medical Income for Consulting $10,000‐19,999

CRV_00035298 Philipp TausskyAssociate Professor and Co‐Investigator

StrokeNet cIRB Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3 (DEFUSE 3) Covidien Income for Consulting $60,000‐79.999

CRV_00035730 Swomitra MohantyAssistant Professor and Principal Investigator TB Breathalyzer

Nanosynth Materials and Sensors Inc




FilmArray Direct: Rapid Diagnosis of Antimicrobial‐Resistant Pathogens from Blood N/A Intellectual Property


CRV_00036825 Douglas Adler Professor and Principal InvestigatorClinical feasibility and efficacy of a new digital single‐operator peroral cholangiopancreatioscopy system: a multicenter registry Boston Scientific Income for Consulting $10,000‐19,999

CRV_00036990 Swomitra MohantyAssociate Professor and Principal Investigator

Non‐invasive TB Triage and Patient Mapping Platform Using Breath via Low‐Cost Titanium Dioxide Nanotube Sensor N/A Intellectual Property


CRV_00036993 Luming ZhouResearch Associate and Co‐Investigator

Multi‐Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics N/A Intellectual Property


CRV_00037314 Ken Johnson Professor and Co‐InvestigatorComparison of Effect Site Concentrations of Anesthetic Agents with Processed Electroencephalography

Medical Visualizations



CRV_00037433 Bryan StoneProfessor (Clinical) and Principal Investigator

Transient Receptor Potential (TRP) Ion Channel Gain of Function Polymorphisms in Pollution Associated Asthma Exacerbations N/A Intellectual Property



VIP‐S ‐ CAIN457AUS02 ‐ A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study to evaluate the effect of secukinumab on aortic vascular inflammation and cardiometabolic biomarkers after 12 weeks of treatment, compared to placebo Novartis



I1F‐MC‐RHBQ ‐ A Multicenter, Randomized, Double‐Blind Study Comparing the Efficacy and Safety of Ixekizumab Versus Placebo in Patients with Moderate‐to‐Severe Genital Psoriasis Eli Lilly and Co.


CRV_00039373 Anne BlaschkeAssociate Professor and Co‐Investigator Sepsis Direct grant N/A Intellectual Property


CRV_00039543 Bradley Katz Professor and Principal InvestigatorSpectacle Tints and Thin‐Films to Reduce Headache Frequency in Patients with Chronic Migraine Axon Optics, LLC



CRV_00039544 Steve Blair Professor and Co‐InvestigatorSpectacle Tints and Thin‐Films to Reduce Headache Frequency in Patients with Chronic Migraine N/A Intellectual Property


CRV_00039545 Kathleen Digre Professor and Co‐InvestigatorSpectacle Tints and Thin‐Films to Reduce Headache Frequency in Patients with Chronic Migraine N/A Intellectual Property


CRV_00039818 Carl Wittwer Professor and Co‐Investigator

Collection of anonymized whole‐blood samples from BioFire employees for use in the development, verification, and validation of the Infectious Diseases (ID) Fever Panel. N/A Intellectual Property


CRV_00039984 Peter Stevens Professor and Principal Investigator Cozen phenomenon‐resolved with guided growth N/ARoyalty Income from Intellectual Property $60,000‐79.999

CRV_00040027 CAMERON METCALFAssociate Director and Principal Investigator

Developing a Peripherally‐Acting Peptidic Galanin Analog for Treatment of Postoperative Pain N/A Intellectual Property


CRV_00040402 Zachary ImelAssistant Professor and Principal Investigator

Implementation of Technology‐Based Evaluation of Motivational Interviewing

Behavioral Informatix



CRV_00040664 Greg Jones Faculty and Co‐investigatorClinical Text Automatic De‐Identification to Support Large Scale Data Reuse and Sharing Clinacuity



CRV_00040743 Frederick WeltProfessor (Clinical) and Co‐investigator

Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System in Patients at Low Risk for Surgical Aortic Valve Replacement. Medtronic Income for Consulting $10,000‐19,999

CRV_00040820 Andy PeifferResearch Assistant Professor and Co‐investigator Wolf‐Hirschhorn Genotype Correlation Project Lineagen Income for Consulting $40,000‐59,999

CRV_00040825 Jeremy GilillandAssistant Professor and Principal Investigator Fluoroscopic Grid use in Total Hip Arthroplasty

OrthoGrid Technologies




Onyx CFZ013 >> Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma Celgene


CRV_00041427 Karen HoAdjunct Associate Professor and Principal Investigator Wolf‐Hirschhorn Genotype Correlation Project Lineagen Employment $10,000‐19,999

CRV_00041828 Christopher Peters Professor and Co‐Investigator

Evaluation of serum metal ion levels in a series of patients undergoing primary or revision total hip arthroplasty with the G7 Dual Mobility Construct Biomet Income for Consulting $20,000‐39,999

CRV_00041829 Christopher PeltAssociate Professor and Co‐Investigator

Evaluation of serum metal ion levels in a series of patients undergoing primary or revision total hip arthroplasty with the G7 Dual Mobility Construct Biomet Income for Consulting $20,000‐39,999


FLOCK: A software‐development collaboration between Modern Dance, FCS (Autism Research) and the Entertainment Arts and Engineering Program's GApp Lab for Therapeutic Games and Apps NeuroVersity



CRV_00042378 Glenn Prestwich Professor and Co‐Investigator Glycosaminoglycan‐base Therapy For Chronic RhinosinusitisGlycomira Therapeutics




RCT Assessing Pregnancy with Intrauterine Devices for Emergency Contraception

Teva Women's Health



Assessing Technology Skills and Employability in Adolescents and Adults with Autism Spectrum Disorder NeuroVersity



CRV_00043083 Michael Deininger Professor and Co‐Investigator

Novartis CPKC412AUS56X Expanded Access >> An open‐label, multi‐center, Expanded Treatment Protocol of Midostaurin (PKC412) in adult patients with newly diagnosed Fms‐like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who are eligib Novartis Income for Consulting $10,000‐19,999

CRV_00043229 Edward Dudek Professor and Principal Investigator Biomarkers for epileptogenesis after brain injury Epitel Income for Consulting $20,000‐39,999

CRV_00043229 Edward Dudek Professor and Principal Investigator Biomarkers for epileptogenesis after brain injury Epitel



CRV_00043264 Florian Solzbacher Professor and Principal Investigator Pre‐Clinical Development of Smart Hydrogels Sentiomed Equity InterestValue cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00044022 Mary ScholandAssociate Professor and Principal Investigator

PRM‐151 A Phase 2 Trial to Evaluate the Efficacy of PRM‐151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

Bristol‐Myers Squibb Equity Interest $40,000‐59,999


A Prospective Trial of the Copper T380 IUD or Oral Levonorgestrel and the Levonorgestrel IUD Initiated with Emergency Contraception

Teva Women's Health Income for Consulting $5,000‐9,999


Novartis CABL001X2101>>A Phase I, Multicenter, Open‐Label Study Of Oral ABL001 In Patients With Chronic Myelogenous Leukemia Or Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia Novartis


CRV_00045056 Michael Kay Professor and Principal InvestigatorOral/Topical D‐peptide TNF Inhibitors for Inflammatory Bowel Disease Navigen Employment $10,000‐19,999

CRV_00045056 Michael Kay Professor and Principal InvestigatorOral/Topical D‐peptide TNF Inhibitors for Inflammatory Bowel Disease Navigen Equity Interest


CRV_00045147 Debra EckertResearch Associate Professor and Co‐Investigator

Oral/Topical D‐peptide TNF Inhibitors for Inflammatory Bowel Disease Navigen Income for Consulting $5,000‐9,999

CRV_00045147 Debra EckertResearch Associate Professor and Co‐Investigator

Oral/Topical D‐peptide TNF Inhibitors for Inflammatory Bowel Disease Navigen Equity Interest


CRV_00045186 Christine AbrahamGraduate Research Assistant and Co‐Investigator

Changes in gait speed and kinematics after participation in a 2 week intensive mobility program in stroke survivors. Veristride Employment $60,000‐79.999

CRV_00045195 Florian Solzbacher Professor and Principal Investigator The Snow Pixel ‐ a micro hotplate snow and precipitation sensor Blackrock Microsystems Income for Consulting >$100,000

CRV_00045195 Florian Solzbacher Professor and Principal Investigator The Snow Pixel ‐ a micro hotplate snow and precipitation sensor N/A Intellectual PropertyValue cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00045195 Florian Solzbacher Professor and Principal Investigator The Snow Pixel ‐ a micro hotplate snow and precipitation sensor Blackrock Microsystems Equity Interest


CRV_00045269 Djordje AtanackovicAssociate Professor and Principal Investigator

Alliance A061402 (CIRB)>>Solitary Plasmacytoma of Bone: Randomized Phase III Trial To Evaluate Treatment With Adjuvant Systemic Treatment And Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy




Alliance A061402 (CIRB)>>Solitary Plasmacytoma of Bone: Randomized Phase III Trial To Evaluate Treatment With Adjuvant Systemic Treatment And Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy Celgene Income for Consulting $10,000‐19,999

CRV_00045271 Tibor KovacsovicsProfessor (Clinical) and Co‐investigator

Alliance A061402 (CIRB)>>Solitary Plasmacytoma of Bone: Randomized Phase III Trial To Evaluate Treatment With Adjuvant Systemic Treatment And Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy Celgene



Alliance A061402 (CIRB)>>Solitary Plasmacytoma of Bone: Randomized Phase III Trial To Evaluate Treatment With Adjuvant Systemic Treatment And Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy Novartis


CRV_00045558 PING MENResearch Associate and Principal Investigator

New therapeutics targeting skeletal excessive Fe for thalassemia major bone loss NanoMedic Equity Interest


CRV_00045640 Thomas Higgins Professor and Co‐Investigator"What happens on the back table? Viability and Osteogenic Potential of RIA bone graft as a function of time and temperature." Depuy Sythes Income for Consulting $10,000‐19,999

CRV_00046342 Michael YUAssociate Professor and Principal Investigator

Imaging Prostate Cancer Microenvironment by Collagen Hybridization 3Helix Equity Interest



Study and Application of Collagen Mimetic Peptide‐Collagen Hybridization 3Helix Equity Interest


CRV_00046344 Michael YUAssociate Professor and Principal Investigator Collagen‐Targeted Therapeutics of Cathepsin Inhibitors 3Helix Equity Interest


CRV_00046545 Mary ScholandAssociate Professor and Principal Investigator

A Phase 2 Trial to Evaluate the Efficacy of PRM‐151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

Bristol‐Myers Squibb Equity Interest $40,000‐59,999

CRV_00046750 Jayant AgarwalAssociate Professor and Co‐Investigator TCIP Vessel Coupling N/A Intellectual Property



NRG/ECOG/ACRIN/NCI EAY131‐X (CIRB)>> MATCH Treatment Subprotocol X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations



NRG/ECOG/ACRIN/NCI EAY131‐Z1D (CIRB)>>Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)


CRV_00046950 Jeremiah AltAssistant Professor and Principal Investigator

A Novel Glycosaminoglycan‐Based Therapeutic for Chronic Rhinosinusitis

Glycomira Therapeutics Equity Interest $10,000‐19,999

CRV_00047142 Swomitra MohantyAssistant Professor and Principal Investigator

Rapid Monitoring and Assessment of Tubercuolosis Treatment at the Point of Care Using Breath

Nanosynth Materials and Sensors Inc Fees for Research $5,000‐9,999


Rapid Monitoring and Assessment of Tubercuolosis Treatment at the Point of Care Using Breath





Pilot Clinical Evaluation of the FilmArray® Fever Panel

N/A Intellectual PropertyValue cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00047508 Bruce Gale Professor and Principal InvestigatorMicrofluidic Devices for Early (less than 48 hpf), Non‐destructive Zebrafish Genotyping NanoNC Equity Interest $40,000‐59,999

CRV_00047508 Bruce Gale Professor and Principal InvestigatorMicrofluidic Devices for Early (less than 48 hpf), Non‐destructive Zebrafish Genotyping NanoNC Employment $5,000‐9,999

CRV_00047513 Raheel SamuelPost Doctoral Fellow and Co‐Investigator

Microfluidic Devices for Early (less than 48 hpf), Non‐destructive Zebrafish Genotyping NanoNC Employment $20,000‐39,999

CRV_00047513 Raheel SamuelPost Doctoral Fellow and Co‐Investigator

Microfluidic Devices for Early (less than 48 hpf), Non‐destructive Zebrafish Genotyping NanoNC Equity Interest


CRV_00047531 Edward Dudek Professor and Principal InvestigatorA rat electrographic model of organophosphate‐induced seizures to evaluate delayed treatment with novel anticonvulsants Rugen Income for Consulting $5,000‐9,999

CRV_00047962 Himanshu SantResearch Assistant Professor and Principal Investigator

Continuous exosome and oncosome separations using a modified SPLITT system Espira Inc Employment $10,000‐19,999

CRV_00047963 Himanshu SantResearch Assistant Professor and Principal Investigator

A Biodegradable Vascular Coupling Device for End‐to‐End Anastomosis

Microsurgical Innovations Equity Interest



CAIN457A2326 ‐ Clarity ‐ A 52‐week, multicenter, randomized, double‐blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12 weeks of treatment, compared to Novartis


CRV_00048055 Tibor KovacsovicsProfessor (Clinical) and Co‐investigator

Roche Genentech GO29695>>A Phase Ib Study Of The Safety And Pharmacokinetics Of Atezolizumab (Anti Pd L1 Antibody) Alone Or In Combination With An Immumomodulatory Drug and/or Daratumumab In Patients With Multiple Myeloma (Relapsed/Refractory And Post Au Celgene


CRV_00048208 Edward Dudek Professor and Principal Investigator

Use of organophosphate‐induced electrographic seizures in rat pups for screening anticonvulsant drugs for the pediatric population. Rugen Income for Consulting $5,000‐9,999

CRV_00048211 Edward Dudek Professor and Principal InvestigatorA model of organophosphate‐induced electrographic seizures in rat to evaluate delayed treatment with novel anticonvulsants Rugen Income for Consulting $5,000‐9,999

CRV_00048250 Michael RileyGraduate Research Assistant and Co‐Investigator Socioeconomic Status and Learning Transfer in Outdoor Education NOLS Employment $5,000‐9,999

CRV_00048288 Jennifer HeemstraAssociate Professor and Co‐Investigator

Mining Complex Human Fluids for New Potential Protein Biomarkers N/A Intellectual Property


CRV_00048355 Loren Rieth Faculty and Co‐investigator

Development of an integrated array for simultaneous optical stimulation and electrical recording for the study of cortical circuit function in the nonhuman primate brain



A Randomized, Open‐label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses Ariad Income for Consulting $5,000‐9,999

CRV_00048724 Neal PatwariAssistant Professor and Principal Investigator

PlusOne: Prototyping and Validation of a Wireless In Home Breathing Monitor for Prevention of Overdose Deaths

Xandem Technology Equity Interest


CRV_00048742 Neal PatwariAssistant Professor and Principal Investigator Radio‐Based Respiration Monitoring During Sleep

Xandem Technology Equity Interest


CRV_00048955 Mark Yandell Professor and Co‐Investigator GENETIC EPIDEMIOLOGY OF HEMATOLOGICAL MALIGNANCIES Omcia


CRV_00048955 Mark Yandell Professor and Co‐Investigator GENETIC EPIDEMIOLOGY OF HEMATOLOGICAL MALIGNANCIES Omcia



CRV_00048955 Mark Yandell Professor and Co‐Investigator GENETIC EPIDEMIOLOGY OF HEMATOLOGICAL MALIGNANCIES IDbyDNA




THERAPEUTIC DRUG MONITORING OF CHRONIC MYELOID LEUKEMIA PATIENTS ON TYROSINE KINASE INHIBITOR THERAPY USING SCALP HAIR CONCENTRATIONS Novartis Income for Consulting $10,000‐19,999


THERAPEUTIC DRUG MONITORING OF CHRONIC MYELOID LEUKEMIA PATIENTS ON TYROSINE KINASE INHIBITOR THERAPY USING SCALP HAIR CONCENTRATIONS Ariad Income for Consulting $5,000‐9,999


AbbVie M15‐538>> A Phase 2, Open‐Label, Multi‐Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Amgen


CRV_00049098 Bradley Katz Professor and Principal InvestigatorSpectacle Tints and Thin‐Films to reduce headache frequency in patients with chronic migraine Axon Optics, LLC




Ariad AP24534‐14‐203>>A Randomized, Open‐label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses Ariad Income for Consulting $5,000‐9,999

CRV_00049463 Gabor Marth Professor and Co‐Investigator Utah Genome ProjectFrameshift Labs, LLC



CRV_00049485 Gerald Krueger Professor and Principal Investigator Psoriasis Research Fellowship Abbvie

Income for Consulting/Education/Speaking/Expert Witness $10,000‐19,999


Focus group evaluation of a prototype app for young adults with autism NeuroVersity Equity Interest


CRV_00049572 Gregory ClarkAssociate Professor and Principal Investigator Embodied Neuroprostheses N/A Intellectual Property


CRV_00049573 Gregory ClarkAssociate Professor and Co‐Investigator

Sensory‐Motor Integration via Recording and Stimulating Arm Nerves N/A Intellectual Property


CRV_00049575 Gregory ClarkAssociate Professor and Co‐Investigator

Can an array of micro‐electrodes implanted in a human nerve record neural signals and provide sensory feedback useful for controlling a prosthetic device? N/A Intellectual Property


CRV_00049705 David TurokAssociate Professor (Clinical) and Princial Investigator Clinical Evaluation of Long‐Acting Reversible Contraceptives

Teva Women's Health


CRV_00050130 Michael Deininger Professor and Principal Investigator Stopping Tyrosine Kinase Inhibitors in CML Patients Novartis Income for Consulting $10,000‐19,999


Development of Incubator with VOC Sensor for Rapid Culture Assessment




CRV_00050145 Michael Kay Professor and Principal Investigator Preclinical development of a potent D‐peptide RSV inhibitor Navigen Employment $10,000‐19,999

CRV_00050145 Michael Kay Professor and Principal Investigator Preclinical development of a potent D‐peptide RSV inhibitor Navigen Equity InterestValue cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00050203 Frederick WeltProfessor (Clinical) and Co‐investigator Evolut R Low Risk Study Medtronic


CRV_00050220 Glenn Prestwich Professor and Principal InvestigatorMECHANISMS OF HYALURONAN SIGNALING AND TURNOVER IN PROSTATE CANCER




CRV_00050448 Stavros DrakosAssociate Professor and Co‐Investigator

A multicenter, randomized, double‐blind, parallel group, active‐controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II‐IV) with preserved ejection fraction Novartis Income for Consulting $5,000‐9,999

CRV_00050594 Mark Yandell Professor and Co‐Investigator Metagenomic approach to the evaluation of myocarditis IDbyDNA



CRV_00050595 Robert SchlabergAssistant Professor and Co‐Investigator Metagenomic approach to the evaluation of myocarditis IDbyDNA



CRV_00050601 Troy AndersenAssociate Professor (Lecturer) and Principal Investigator Memory Care Partner PAMS, Inc.



CRV_00050813 Jindrich KopecekDistinguished Professor and Principal Investigator

Initiation of Apoptosis in Rituximab‐Resistant Cell Lines Mediated by Drug‐Free Therapeutics Bastion Biologics



CRV_00050890 Stavros DrakosAssociate Professor and Co‐Investigator Entresto (LCZ696) In Advanced Heart Failure (LIFE Study) Novartis Income for Consulting


CRV_00051049 Jennifer HeemstraAssociate Professor and Principal Investigator

A New Sample Preparation Method to Delve Deeper into the Proteome N/A Intellectual Property


CRV_00051269 Russell ButterfieldAssistant Professor and Principal Investigator

An Open‐Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects with Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy Biogen‐Idec



Expanded Access Program (EAP) to provide Nusinersen to Patients with Infantile‐onset Spinal Muscular Atrophy (SMA) Biogen‐Idec



An Open‐Label Study to Assess the Efficacy, Safety, Tolerability,

and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects

With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy Biogen‐Idec



Expanded Access Program (EAP) to provide Nusinersen to Patients With Infantile‐onset Spinal Muscular Atrophy (SMA) Biogen‐Idec


CRV_00051281 Russell ButterfieldAssistant Professor and Co‐Investigator

Health Endpoints and Longitudinal Progression in Myotonic Dystrophy type 1(HELP‐DM) Biogen‐Idec



Health Endpoints and Longitudinal Progression in Congenital Myotonic Dystrophy (HELP‐CDM) Biogen‐Idec


CRV_00051402 Jutta DeiningerNurse Practitioner and Co‐Investigator

Novartis CLEE011xUS29 TRINITI‐1>> A Phase I/II, single arm, open‐label study of Ribociclib in Combination with Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women with HR+, HER2‐ Locally Advanced or Metastatic Breast Cancer Following Novartis Income for Consulting $10,000‐19,999

CRV_00051407 Gabor Marth Professor and Principal InvestigatorEmpowering real‐time, web‐based genomic big data analysis at commercial scale

Frameshift Labs, LLC




An Open‐label Extension Study for Patients with Spinal Muscular

Atrophy who Previously Participated in Investigational Studies of ISIS 396443 Biogen‐Idec



A Phase 3, Randomized, Double‐blind, Sham‐Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients with Infantile‐onset Spinal Muscular Atrophy Biogen‐Idec



An Open‐label Study to Assess the Safety and Tolerability of ISIS 396443 in Patients with Spinal Muscular Atrophy who Previously Participated in ISIS 396443‐CS2 or ISIS 396443‐CS10 Biogen‐Idec


CRV_00051703 Aaron QuinlanAssociate Professor and Co‐Investigator GENETIC EPIDEMIOLOGY OF HEMATOLOGICAL MALIGNANCIES Base2 Genomics



CRV_00051773 Aaron QuinlanAssociate Professor and Co‐Investigator Genetic risk factors in suicide and depression Base2 Genomics



CRV_00051858 Troy AndersenAssociate Professor (Lecturer) and Co‐Investigator

EXEMPTION UMBRELLA: Clinical Outcomes and Health Systems in Cognitive Care PAMS, Inc.



CRV_00052152 Orly AlterAssociate Professor and Principal Investigator

Multi‐Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics Eigengene, Inc.



CRV_00052162 Jeremy GilillandAssistant Professor and Principal Investigator

Intraoperative Data Collection for the use of a Novel Digital Fluoroscopic Grid

OrthoGrid Technologies Equity Interest $5,000‐9,999

CRV_00052163 Mike AndersonResearch Scientist and Co‐Investigator

Intraoperative Data Collection for the use of a Novel Digital Fluoroscopic Grid

OrthoGrid Technologies Equity Interest



AbbVie Inc. M15‐656>> A Randomized, Double‐Blind, Placebo Controlled Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Elderly Subjects with Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy Celgene


CRV_00052546 Robert SchlabergAssistant Professor and Principal Investigator Reproducibility of pathogen detection by metagenomics IDbyDNA



CRV_00052631 Michael Deininger Professor and Principal InvestigatorProspective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CSF3R Incyte


CRV_00052822 Terry BoxAssociate Professor (Clinical) and Co‐Investigator

GS‐US‐384‐1944: A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) Gilead Income for Consulting $20,000‐39,999

CRV_00053450 David WarrenResearch Associate Professor and Co‐Investigator

Can an array of micro‐electrodes implanted in a human nerve record neural signals and provide sensory feedback useful for controlling a prosthetic device? N/A Intellectual Property


CRV_00053467 David WarrenResearch Associate Professor and Co‐Investigator

Sensory‐Motor Integration via Recording and Stimulating Arm Nerves N/A Intellectual Property


CRV_00053469 David WarrenResearch Associate Professor and Co‐Investigator Embodied Neuroprostheses N/A Intellectual Property



Incyte INCB54828‐203>> A Phase 2, Open‐Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement Incyte


CRV_00053817 Irene De BiaseAssistant Professor (Clinical) and Co‐Investigator Identification and Description of LAL‐D Patients in an EHR Database Alexion


CRV_00054303 Mark Yandell Professor and Co‐Investigator

The Metagenomics of Pediatric Eosinophilic Esophagitis (EoE): A Pan‐Microbial Survey and T‐Cell Receptor Analysis from Esophageal Tissue IDbyDNA



CRV_00054305 Robert SchlabergAssistant Professor and Co‐Investigator

The Metagenomics of Pediatric Eosinophilic Esophagitis (EoE): A Pan‐Microbial Survey and T‐Cell Receptor Analysis from Esophageal Tissue IDbyDNA



CRV_00054321 Carl Wittwer Professor and Co‐InvestigatorTesting of De‐Identified Clinical Specimens for use in Product Development and Clinical Studies for the Fever Panel. N/A Intellectual Property



Collection of anonymized urine samples from BioFire employees for use in the development, verification, and validation of the Infectious Diseases (ID) Fever Panel. N/A Intellectual Property


CRV_00054464 Joel CooperResearch Associate Professor and Co‐Investigator Assessment of assistance systems on the road Red Scientific Income for Consulting $5,000‐9,999

CRV_00054464 Joel CooperResearch Associate Professor and Co‐Investigator Assessment of assistance systems on the road Red Scientific Equity Interest



Clinical Evaluation of the FilmArray® Global Fever (GF) Panel – BioFire Defense Site‐Specific Activities

N/A Intellectual PropertyValue cannot be readily determined through reference to public prices or other reasonable measures of fair market value.


NRG/ECOG/ACRIN/NCI EAY131‐J (CIRB)>>MATCH Treatment Subprotocol J: Trastuzumab and Pertuzumab (HP) in Patients with Non‐Breast, Non‐Gastric/GEJ Cancers with HER2 Amplification




Novartis CLAG525X2101C>>A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies Novartis Income for Consulting $10,000‐19,999


A phase I, multicenter, open‐label study of oral ABL001 in patients with chronic myelogenous leukemia or Philadelphia Chromosome‐positive acute lymphoblastic leukemia Novartis Income for Consulting $10,000‐19,999


Incyte INCB 18424‐272 >> A Double‐Blind, Double‐Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects with Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea Incyte Income for Consulting $10,000‐19,999

CRV_00054922 Brook MartinResearch Associate Professor and Principal Investigator

Influence of an expanded mandatory bundled payment program on patient‐reported outcomes, episode‐of‐care costs, procedure volume, and safety.

Gold Standard Research, LLC Equity Interest >$100,000

CRV_00055132 Aaron QuinlanAssociate Professor and Principal Investigator Novel DNA damage response gene from genomic screening Base2 Genomics



CRV_00055250 Bryan JonesResearch Associate Professor and Principal Investigator Retinal Remodeling N/A Intellectual Property


CRV_00055376 Paul Bernstein Professor and Principal Investigator Biochemistry and Pharmacology of the Macular Carotenoids N/A Intellectual PropertyValue cannot be readily determined through reference to public prices or other reasonable measures of fair market value.


A multi‐center, single‐blind, randomized clinical trial to compare two copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard

Teva Women's Health Employment $10,000‐19,999


Rates of contraceptive failure when unprotected intercourse has occurred 6‐14 days prior to contraceptive initiation


CRV_00055929 K‐T VARLEYAssistant Professor and Principal Investigator

A partnership to enable clinical ctDNA testing for breast cancer recurrence Kailos Genetics Income for Consulting $20,000‐39,999

CRV_00055929 K‐T VARLEYAssistant Professor and Principal Investigator

A partnership to enable clinical ctDNA testing for breast cancer recurrence Kailos Genetics



CRV_00056194 Gabor Marth Professor and Principal InvestigatorIntegration of iobio genetic analysis tools into ARUP diagnostic pipelines




CRV_00056247 Sheila CrowellAssociate Professor and Principal Investigator

Dialectical behavior therapy skills in schools: Skills training for emotion problem solving for adolescents (DBT STEPS‐A)

Utah Center for Evidence Based Treatment

Income for Clinical Services $10,000‐19,999

CRV_00056247 Sheila CrowellAssociate Professor and Principal Investigator

Dialectical behavior therapy skills in schools: Skills training for emotion problem solving for adolescents (DBT STEPS‐A)

Utah Center for Evidence Based Treatment Equity Interest


CRV_00056491 Richard CawthonResearch Associate Professor and Principal Investigator Novel Quantitative PCR Assays of Telomeric DNA N/A Intellectual Property


CRV_00056856 Sean RunnelsAssistant Professor (Clinical) and Principal Investigator

Airway exchange catheter tip control in the trachea with and without videolaryngoscopy in airway mannequins Through the cords Equity Interest


CRV_00056924 Richard CawthonResearch Associate Professor and Principal Investigator Novel Quantitative PCR Assays of Telomeric DNA N/A Intellectual Property


CRV_00057012 Mark Yandell Professor and Co‐Investigator A scalable, integrative, multi‐omic analysis platform Omcia


CRV_00057012 Mark Yandell Professor and Co‐Investigator A scalable, integrative, multi‐omic analysis platform Omcia



CRV_00057167 Paul Bernstein Professor and Principal InvestigatorSpark Therapeutics: Natural History of Individuals with Retinal Degeneration due to Mutations in the CHM Gene Spark Therapeutics


CRV_00057481 Eric Schmidt Professor and Principal Investigator Symbiosis and Chemical Diversity GenerationSynthetic Biodesign




CAIN457AUS07 ‐ ObePso‐S ‐ A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study to explore changes in subcutaneous adipose tissue and modulation of skin inflammation after 12 weeks of treatment with secukinumab, compared to pl Novartis


CRV_00057719 Charles Atwood Professor and Principal InvestigatorEvidence‐based and evidence‐generating approaches to understanding STEM learning across the Western States N/A Intellectual Property


CRV_00057767 Michael RileyGraduate Research Assistant and Principal Investigator Exploring the Developmental Networks of Outdoor Educators NOLS Employment $5,000‐9,999


The Influence of an expanded bundled payment program on patient‐reported outcomes, episode‐of‐care costs, procedure volume, and safety.

Gold Standard Research, LLC Equity Interest >$100,000


Pilot Evaluation of the FilmArray® Childhood Systemic Infection (CSI) Panel N/A Intellectual Property


CRV_00058156 Mohamed Salama Professor and Principal Investigator Microscopic Cellular Features of Whole Blood Samples Techcyte



CRV_00058175 Thomas Higgins Professor and Co‐InvestigatorWhat happens on the back table? Viability of RIA graft as a function of time and temperature Depuy Sythes Income for Consulting $10,000‐19,999

CRV_00058340 David TurokAssistant Professor (Clinical) and Co‐Investigator

Highly Effective Reversible Contraceptive Initiative – Salt Lake Stories: A Qualitative Study


CRV_00059300 Mark Jensen Student and Co‐InvestigatorDevelopment and Initial Testing of Novel Silk‐elastinlike Protein Polymers for Aneurysm Interveintion N/A Intellectual Property


CRV_00059352 James HotalingAssistant Professor and Co‐Investigator

Validation study of urine flow rate monitoring with novel device: StreamDx. N/A Intellectual Property


CRV_00059353 James HotalingAssistant Professor and Co‐Investigator StreamDx N/A Intellectual Property


CRV_00059562 Sean MulvihillAssociate Vice President and Principal Investigator A Feasibility Study for the Early Detection of Pancreatic Cancer N/A Intellectual Property $10,000‐19,999

CRV_00059582 Matthew FirpoResearch Associate Professor and Co‐Investigator A Feasibility Study for the Early Detection of Pancreatic Cancer N/A Intellectual Property


CRV_00059746 Paul Bernstein Professor and Principal InvestigatorNatural History of Individuals with Retinal Degeneration due to Mutations in the CHM Gene Spark Therapeutics


CRV_00060157 Gabor Marth Professor and Co‐InvestigatorWeb tools to enhance physician‐driven diagnostic interpretation of genomic patient data




CRV_00060451 Edward Dudek Professor and Principal Investigator Anticonvulsant screening using chronic epilepsy models Epitel Income for Consulting $20,000‐39,999

CRV_00060451 Edward Dudek Professor and Principal Investigator Anticonvulsant screening using chronic epilepsy models Epitel




A Phase 2, Open‐Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement Incyte


CRV_00060653 Michael TananaResearch Assistant Professor and Co‐investigator

Iterative development of Computerized Motivational Interviewing Feedback. Lyssn.io



CRV_00060672 Geoffrey MillerAdjunct Instructor and Co‐investigator

Determination of serum L‐carnitine levels pre, during, and post intravenous infusion of L‐carnitine with varying infusion volumes.

Sports Medicine Research and Testing Laboratory Employment $60,000‐79.999

CRV_00060673 Geoffrey MillerAdjunct Instructor and Co‐investigator

Assessment of Biological Passport Profiles following an Ironman Event

Sports Medicine Research and Testing Laboratory Employment $60,000‐79.999

CRV_00060689 Zachary ImelAssociate Professor and Principal Investigator

DEVELOPMENT AND FEASIBILITY OF COMPUTER BASED FIDELITY MONITORING FOR MI. Lyssn.io




Implementation of Technology‐based Evaluation of Motivational Interviewing Lyssn.io




Iterative development of Computerized Motivational Interviewing Feedback. Lyssn.io




A Phase 2, Open‐Label, Multi‐Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Amgen



Alliance Foundation Trials AFT‐38>>A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti‐HER2 Therapy + Endocrine Therapy vs. Anti‐HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Recept Pfizer Income for Consulting $10,000‐19,999

CRV_00060893 Mark Yandell Professor and Co‐Investigator Software for exploring all forms of genetic variation in any speciesFabric Genomics (Omicia)


CRV_00060893 Mark Yandell Professor and Co‐Investigator Software for exploring all forms of genetic variation in any species Fabric Genomics



CRV_00061132 Gabor Marth Professor and Principal InvestigatorIOBIO: Web‐based, interactive tools for real‐time analysis in genomic big data




CRV_00061310 Aaron QuinlanAssociate Professor and Co‐Investigator

IOBIO: Web‐based, interactive tools for real‐time analysis in genomic big data Base2 Genomics



CRV_00061317 Aaron QuinlanAssociate Professor and Principal Investigator Software for exploring all forms of genetic variation in any species Base2 Genomics




A Randomized, Double‐blind, Placebo Controlled, Study of Venetoclax in Combination with Azacitidine VS Azacitidine in Treatment with NaÃ ÂÃ Âˉve Elderly subjects with Acute Myeloid Leukemia who are ineligible for Standard Induction Therapy Celgene


CRV_00061593 James HotalingAssistant Professor and Principal Investigator

Stream Dx: accurate and efficient, point‐of‐care uroflometry for improved diagnosis, monitoring, and post‐treatment evaluation of LUTS StreamDx




Alliance Foundation Trials AFT – 05 >> PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive ( Pfizer Income for Consulting $10,000‐19,999

CRV_00061669 David TurokAssociate Professor (Clinical) and Princial Investigator Midcareer Investigator Award in Patient‐Oriented Research



Novartis CABL001A2301>>A Phase 3, Multi‐Center, Open‐Label, Randomized Study Of Oral ABL001 Versus Bosutinib In Patients With Chronic Myelogenous Leukemia In Chronic Phase (CML‐CP), Previously Treated With 2 Or More Tyrosine Kinase Inhibitors Pfizer



Novartis CABL001A2301>>A Phase 3, Multi‐Center, Open‐Label, Randomized Study Of Oral ABL001 Versus Bosutinib In Patients With Chronic Myelogenous Leukemia In Chronic Phase (CML‐CP), Previously Treated With 2 Or More Tyrosine Kinase Inhibitors Novartis


CRV_00061897 Joshua CatesResearch Computer Scientist and Co‐Investigator

New 3D and 4D Image‐Based Clinical Measures of Atrial Structural and Functional Remodeling in Atrial Fibrillation Marrek, Inc



CRV_00062080 Michael TananaResearch Assistant Professor and Co‐investigator

Implementation of Technology‐Based Evaluation of Motivational Interviewing Lyssn.io Equity Interest



Implementation of Technology‐Based Evaluation of Motivational Interviewing Lyssn.io



CRV_00062097 Gabor Marth Professor and Principal InvestigatorWeb tools for physician‐driven diagnostic interpretation of genomic patient data




CRV_00062488 Terry BoxAssociate Professor (Clinical) and Co‐Investigator

GS‐US‐384‐1943: A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis Gilead



AbbVie M16‐109>>A Phase 2 Single‐Arm, Open‐Label Study Evaluating Tolerability and Efficacy of Navitoclax in Combination with Ruxolitinib in Subjects with Myelofibrosis Incorporating Amendments Incyte



RADICAL IIA: Evaluation of a Rapid Diagnostic Test for the Categorization of Acute Respiratory Illness N/A Intellectual Property


CRV_00063164 Michael Kay Professor and Co‐InvestigatorCenter for the Structural Biology of Cellular Host Elements in Egress, Trafficking, and Assembly of HIV (CHEETAH Center) Navigen Income for Consulting $10,000‐19,999

CRV_00063164 Michael Kay Professor and Co‐InvestigatorCenter for the Structural Biology of Cellular Host Elements in Egress, Trafficking, and Assembly of HIV (CHEETAH Center) Navigen



CRV_00063400 R. Lor Randall Professor and Co‐Investigator

A Double‐blind, Randomized, Placebo‐controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath Daiichi Sankyo Income for Consulting $10,000‐19,999

CRV_00063405 R. Lor Randall Professor and Co‐Investigator

Daiichi Sankyo PLX108‐10>>A Double‐blind, Randomized, Placebo‐controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath ENLIVEN Daiichi Sankyo Income for Consulting $10,000‐19,999

CRV_00063610 Lucinda Bateman Faculty and Co‐investigatorUsing the UPDB to Increase Understanding of Chronic Fatigue Syndrome and Fibromyalgia

Bateman Home Health Center for Excellence Employment $80,000‐$99,999

CRV_00063685 Howard Colman Professor and Co‐InvestigatorAlliance A071601(CIRB)>>Phase II trial of BRAF/MEK inhibitors in papillary craniopharyngiomas



CRV_00064098 Stephen SummersAssistant Professor and Co‐Investigator

Stream Dx: accurate and efficient, point‐of‐care uroflometry for improved diagnosis, monitoring, and post‐treatment evaluation of LUTS StreamDx Equity Interest


CRV_00064251 Gerald GleichResearch Professor and Prinicipal Investigator

GSK 205203: A multi‐centre, open‐label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622 GlaxoSmithKline Income for Consulting $5,000‐9,999


A multi‐center, randomized, double‐blind, placebo controlled, parallel group study to compare cessation versus continuation of long‐term mepolizumab treatment in patients with severe eosinophilic asthma‐201810 GlaxoSmithKline Income for Consulting $5,000‐9,999


(GSK 201810) A multi‐center, randomized, double‐blind, placebo controlled, parallel group study to compare cessation versus continuation of long‐term mepolizumab treatment in patients with severe eosinophilic asthma (201810) GlaxoSmithKline Income for Consulting $5,000‐9,999


GSK 204959: An open‐label, single arm, repeat dose, multi‐centre study to evaluate the use of an autoinjector for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma (Study 204959) GlaxoSmithKline Income for Consulting $5,000‐9,999

CRV_00064292 Scott Summers Professor and Principal InvestigatorDihydroceramide Desaturase‐1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases

Centaurus Therapeutics Income for Consulting $10,000‐19,999

CRV_00064292 Scott Summers Professor and Principal InvestigatorDihydroceramide Desaturase‐1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases

Centaurus Therapeutics Equity Interest


CRV_00064808 Robert SchlabergAssistant Professor and Co‐Investigator Metagenomics Approach to the Evaluation of Kawasaki Disease IDbyDNA

Income for Consulting/Advisory Board/Equity Interest/Intellectual Property $60,000‐79.999

CRV_00064888 Aaron QuinlanAssociate Professor and Principal Investigator

A powerful web‐based discovery platform for rare disease genomics Base2 Genomics




The Influence of an expanded bundled payment program on patient‐reported outcomes, episode‐of‐care costs, procedure volume, and safety. Statix, LLC Equity Interest



Influence of an expanded mandatory bundled payment program on patient‐reported outcomes, episode‐of‐care costs, procedure volume, and safety. Statix, LLC Equity Interest


CRV_00065477 Carol Bruggers Professor and Co‐ Investigator Self‐Management Epilepsy Questionnaire Epicadence




A multi‐centre, open‐label extension, safety study of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622,Ã¢Â Â Protocol no. 205203 GlaxoSmithKline Income for Consulting $5,000‐9,999

CRV_00066429 Pegah AfraAssociate Professor and Principal Investigator Self‐Management Epilepsy Questionnaire #N/A Intellectual Property


CRV_00066430 Matthew SweneyAssistant Professor (Clinical) and Co‐Investigator Self‐Management Epilepsy Questionnaire #N/A Intellectual Property


CRV_00066434 Kent BachusResearch Professor and Co‐Investigator

Percutaneous Osseointegrated Docking System for Above Elbow Amputees...IPA Castolene #N/A Intellectual Property


CRV_00066439 Sean RunnelsAssistant Professor (Clinical) and Principal Investigator

THE EFFECTS OF A UNIQUE COLOR ZONE SYSTEM ON ENDOTRACHEAL TUBE DEPTH CONTROL DURING EMERGENCY INTUBATIONS WITH VIDEO LARYNGOSCOPY IN AIRWAY MANNEQUINS Through the cords Equity Interest


CRV_00066547 Peter Stevens Professor and Principal Investigator Guided growth for proximal tibial recurvatum OrthofixRoyalty Income from Intellectual Property >$100,000

CRV_00066629 Kent BachusResearch Professor and Principal Investigator

Biomechanical Testing of Orthopaedic Devices Using Decedent Tissue Models #N/A Intellectual Property


CRV_00066990 Kent BachusResearch Professor and Principal Investigator

The variability of the residual bone and soft tissues of amputated extremities following traumatic amputation #N/A Intellectual Property


CRV_00067454 Florian Solzbacher `Plasma‐assisted atomic layer deposition of alumina and Parylene‐C bi‐layer encapsulation


Income for Consulting/Intellectual Property >$100,000



Income for ConsultingIntellectual Property >$100,000

CRV_00067821 Tibor KovacsovicsProfessor (Clinical) and Co‐Investigator

Amgen 20150161>>A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia Celgene



LLS BAML‐16‐001‐M1>> (WIRB) A Master Protocol for Biomarker‐Based Treatment of AML (The Beat AML Trial) Celgene


CRV_00068559 C. Matthew Peterson Professor and Co‐Investigator

Development of novel polymer‐based, nanotechnology, delivery systems for targeted delivery to overcome drug resistance in ovarian cancer and gynecological malignancies utilizing genital tract (vaginal, cervical, endometrial, peritoneal and ovarian) tissu TheraTarget Equity Interest


CRV_00068823 K‐T VARLEYAssistant Professor and Co‐Investigator Cancer Genetics Study Kailos Genetics

Income for Consulting/Intellectual Property $20,000‐39,999

CRV_00069196 Robert Burks Professor and Co‐InvestigatorLong Term Patient Reported Outcomes for the Shoulder and Elbow Population KATOR Equity Interest



Pilot Evaluation of the FilmArray Childhood Systemic Infection (CSI) Panel N/A Intellectual Property


CRV_00069213 Mark Yandell Professor and Co‐InvestigatorA Community Driven Framework for Genome Based Clinical Diagnostics Fabric Genomics

Income for Consulting/Advisory Board/Equity Interest/Intellectual Property $20,000‐39,999

CRV_00069222 Mark Yandell Professor and Principal InvestigatorVAAST+: Tool for variant prioritization, risk assessment and disease‐gene finding Fabric Genomics


CRV_00069223 Mark Yandell Professor and Co‐InvestigatorIntegrating Genomic and Clinical Approaches to Sudden Death in the Young Fabric Genomics


CRV_00069226 Mark Yandell Professor and Co‐Investigator Bridging the Gap between Genomics and Clinical Outcomes in CHD Fabric Genomics


CRV_00069227 Mark Yandell Professor and Co‐InvestigatorPEDIATRIC CARDIAC GENOMICS CONSORTIUM: CONGENITAL HEART DISEASE GENETIC NETWORK STUDY (CHD GENES) Fabric Genomics


CRV_00069229 Mark Yandell Professor and Co‐Investigator Biological Determinants of Brain Variation in Autism Fabric Genomics


CRV_00069233 Mark Yandell Professor and Co‐Investigator Pediatric Cardiology Genotype‐Phenotype Core Fabric Genomics


CRV_00069234 Mark Yandell Professor and Co‐InvestigatorGenetic, Molecular, and Cellular Mechanisms Regulating Development of Congenital Diaphragmatic Hernias Fabric Genomics


CRV_00069235 Mark Yandell Professor and Co‐Investigator Genetics Of Autism Fabric Genomics


CRV_00069236 Mark Yandell Professor and Co‐Investigator Utah Genome Project Fabric Genomics


CRV_00069474 Jeremy GilillandAssistant Professor and Co‐Investigator

Clinical and Biomechanical Outcomes Following Total Knee Arthroplasty Smith & Nephew Income for Consulting $5,000‐9,999

CRV_00069699 Robert Tashjian Professor and Principal InvestigatorEfficacy of the BioWick SureLock Implant for the Reattachment of Soft Tissue to Bone in Subject Undergoing Rotator Cuff Repairs Zimmer Biomet Income for Consulting $10,000‐19,999

CRV_00069707 Robert Tashjian Professor and Principal Investigator Functional and Radiographic Outcomes after Shoulder Surgery

Shoulder Innovations, Wright Medical Technology, Zimmer Biomet

Income for Consulting/Equity Interest $40,000‐59,999; $10,000‐19,999; $10,000‐19,999


Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone, Versus Lenalidomide, Bortezomib, and Dexamethasone, in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High Dose Chemotherapy, Autologous Stem Cell Transplantation




OSU 14031/NCI 9603>>Pilot Trial Evaluating the Combination of Reolysin and Carfilzomib in Mul ple Myeloma

Amgen/OnyxIncome for Consulting/Speaking $5,000‐9,999


Janssen 54767414MMY2004>>Phase 2, Randomized, Open‐Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D‐RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible

Janssen Pharmaceutical Inc Income for Consulting $10,000‐19,999

CRV_00069808 Scott Summers Professor and Principal Investigator The Role of Ceramides in Skeletal MuscleCentaurus Therapeutics

Income for Consulting/Equity Interest/Employment $20,000‐39,999

CRV_00069918 Scott Summers Professor and Principal Investigator Role of Ceramides in Skeletal MuscleCentaurus Therapeutics

Income for Consulting/Equity Interest/Employment $20,000‐39,999


Study 200622: A randomized, double‐blind, placebo‐controlled study to investigate the efficacy and safety of mepolizumab in the treatment of adolescent and adult subjects with severe hypereosinophilic syndrome GlaxoSmithKline Income for Consulting $5,000‐9,999


Roche Genentech GO29695>>A Phase Ib Study Of The Safety And Pharmacokinetics Of Atezolizumab (Anti Pd L1 Antibody) Alone Or In Combination With An Immunomodulatory Drug and/or Daratumumab In Patients With Multiple Myeloma (Relapsed/Refractory And Post Au



OSU 14031/NCI 9603>>Pilot Trial Evaluating the Combination of Reolysin and Carfilzomib in Mul ple Myeloma

Amgen


CRV_00070461 George Rodgers Professor and Principal Investigator

BIV 0‐3 Cardina: A Pivotal Open‐Label Multicenter Study to Assess the Efficacy and Safety of BIVV009 in Patients with Primary Cold Agglutinin Disease who have a Recent History of Blood Transfusion (Cardina) Bioverativ Income for Consulting $20,000‐39,999


BIV 0‐4 Cadenza A RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED STUDY TOASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITHPRIMARY COLD AGGLUTININ DISEASE WITHOUT A RECENTHISTORY OF BLOOD TRANSFUSION Bioverativ Income for Consulting $20,000‐39,999


A PHASE Ib STUDY OF THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB (ANTI‐PD‐L1 ANTIBODY) ALONE OR IN COMBINATION WITH AN IMMUNOMODULATORY DRUG AND/OR DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA


CRV_00070987 Dennis Parker Professor and Co‐InvestigatorValidation and translation of a non‐invasive, MR‐guided breast cancer therapy #N/A Intellectual Property


CRV_00070993 Allison PayneResearch Associate Professor and Principal Investigator

Validation and translation of a non‐invasive, MR‐guided breast cancer therapy N/A Intellectual Property


CRV_00071050 Mark Yandell Professor and Co‐Investigator GENETIC EPIDEMIOLOGY OF BREAST CANCER Fabric Genomics


CRV_00071083 Stephen SummersAssistant Professor and Principal Investigator Study of urine flow rate monitoring with novel device: Stream Dx. StreamDx Equity Interest


CRV_00071085 Bryan JonesResearch Associate Professor and Principal Investigator Retinal Circuitry N/A Intellectual Property


CRV_00071172 Harry Hill Professor and Principal Investigator

Interferon Gamma (IFN‐gamma, Actimmune) Effects on Variant X‐Linked and Autosomal Recessive Chronic Granulomatous Disease (CDG)

Vidara Therapeutics Income for Speaking $5,000‐9,999

CRV_00071192 Leslie JerominskiSr Laboratory Specialist and Co‐Investigator Genetic risk factors in suicide and depression

Janssen Pharmaceutical Inc Employment $5,000‐9,999

CRV_00071451 Nassir Marrouche Professor and Principal Investigator

Women’s Only Heart Research Ini a ve (WOHRI):Structural and Biometric Factors Influencing Heart Disease in Women

Cardiac Designs and Wavelet Health Equity Interest


CRV_00071834 Douglas SborovAssistant Professor (Clinical) and Co‐Investigator

Onyx CFZ013 >> Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma Celgene



A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia Amgen


CRV_00071953 Mark Yandell Professor and Co‐Investigator Whole Genome Sequencing‐Based Discovery of Genes for Diabetic Kidney Disease Fabric Genomics



Celgene ACE‐MM‐104 >> A Phase 1b Multicenter, Open Label, Dose‐Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Anti‐Tumor Activity of ACY‐1215 (Ricolinostat) in Combination with Pomalidomide and Low‐dose Dexamethasone in Patients wi Celgene



A PIVOTAL,OPEN‐LABEL,MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASEWHO HAVE A RECENT HISTORY OF BLOOD TRANSFUSION Bioverativ Income for Consulting $20,000‐39,999

CRV_00072165 Henry White Professor and Principal Investigator exonuclease‐nanopore platform (RNA) #N/A Intellectual PropertyValue cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00072556 Natalie SilvertonAssistant Professor (Clinical) and Principal Investigator

Noninvasive measurements of renal perfusion during cardiac surgery KSCube



CRV_00072772 Gabor Marth Professor and Co‐InvestigatorWeb tools to enhance physician‐driven diagnostic interpretation of genomic patient data: DNA sequencing and analysis.





Janssen 54767414AMY3001>>A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared with CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis. Janssen

Pharmaceutical Inc Income for Consulting $10,000‐19,999

CRV_00073182 Anthony DonatoAssociate Professor and Principal Investigator

Novel Methodology for Identification of Senolytics that Reduce Age‐Related Disease and Dysfunction

Recursion Pharmaceuticals Equity Interest


CRV_00073209 Mei Yee KohAssistant Professor and Principal Investigator

A novel approach for the selective inhibition of HIF‐2a in kidney cancer Kuda Therapeutics Equity Interest


CRV_00073315 Kai Kuck Professor and Co‐InvestigatorNoninvasive measurements of renal perfusion during cardiac surgery KSCube



CRV_00073456 Kai Kuck Professor and Co‐Investigator Monitor to Detect Kidney Risk KSCube



CRV_00073457 Natalie SilvertonAssistant Professor (Clinical) and Principal Investigator Monitor to Detect Kidney Risk KSCube



CRV_00073736 Erik Jorgensen Professor and Co‐Investigator Regulation of nutrient transportersBruker Materials Group

Income from Consulting/Intellectual Property $10,000‐19,999

CRV_00073748 Pouya HadipourGraduate Research Assistant and Co‐Investigator

The Hemocompatibility Study of Silica Nanoparticles as a function of Size and Surface Properties #N/A Intellectual Property


CRV_00073806 Jeremiah AltAssistant Professor and Principal Investigator

A NOVEL GLYCOSAMINOGLYCAN‐BASED THERAPEUTIC FOR CHRONIC RHINOSINUSITIS


CRV_00074000 Jeremiah AltAssistant Professor and Principal Investigator Sinonasal Tissue Repository



I4V‐MC‐JAIW ‐ A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis Eli Lilly


CRV_00074155 Gerald Krueger Professor and Co‐InvestigatorCorrona‐PSO‐500 Corrona Psoriasis Registry

Abbvie, Eli Lilly, Johnson & Johnson, and Novartis

Income for Consulting/Education/Speaking $10,000‐19,999; $10,000‐19,999;$20,000‐39,999; $20,000‐39,999

CRV_00074162 Hamid Ghandehari Professor and Principal InvestigatorThe Hemocompatibility Study of Silica Nanoparticles as a function of Size and Surface Properties #N/A Intellectual Property


CRV_00074311 Gerald Krueger Professor and Co‐InvestigatorPsoria c Arthri s Research Consor um (PARC)

Abbvie, Eli Lilly, Johnson & Johnson, and Novartis

Income for Consulting/Education/Speaking $10,000‐19,999; $10,000‐19,999;$20,000‐39,999; $20,000‐39,999


I6T‐MC‐AMAK ‐ A Multicenter Study with a Randomized, Double‐Blind, Placebo‐Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderate‐to‐Se Eli Lilly


CRV_00074585 Karen Eilbeck Professor and Co‐Investigator Utah Infertility Registry‐ Polycystic Ovary Syndrome (UIR‐PCOS) IDbyDNA


CRV_00074587 Mark Yandell Professor and Co‐Investigator Utah Infertility Registry‐ Polycystic Ovary Syndrome (UIR‐PCOS) Fabric Genomics


CRV_00074587 Mark Yandell Professor and Co‐Investigator Utah Infertility Registry‐ Polycystic Ovary Syndrome (UIR‐PCOS) IDbyDNA

Equity Interest/Intellectual Property $5,000‐9,999


ENDOMETRIOSIS IMPRINTS (Infertility, Mortality (cancers), Pain, Reproductive outcomes (time to pregnancy, prematurity, preeclampsia, etc), Inheritance patterns (Is endometriosis one or multiple entities?), Noisome Traits (comorbidities) and Symptoms [IMP Fabric Genomics



PS0008 – A Phase 3, Multicenter, Randomized, Double‐Blind Study with an Active‐Controlled Initial Treatment Period Followed by a Dose Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Abbvie


CRV_00074704 KYLE ISAACSONGraduate Research Assistant and Co‐Investigator

The Hemocompatibility Study of Silica Nanoparticles as a function of Size and Surface Properties #N/A Intellectual Property


CRV_00074705 Robert Tashjian Professor and Principal InvestigatorEfficacy of the BioWick™ SureLock™ Implant for the Reattachment of Soft Tissue to Bone in Subjects Undergoing Rotator Cuff Repairs Zimmer Biomet Income for Consulting $10,000‐19,999


Retrospective Investigation of Patient Outcomes Following Total Hip Arthroplasty for Hip Fractures

DJO Surgical, Medcata, Smith & Nephew

Income for Consulting/Education/Speaking $10,000‐19,999; $10,000‐19,999;$10,000‐19,999


Safety Study of Percutaneous Osseointegrated Implants for Prosthetic Attachment DJO Surgical Income for Consulting $10,000‐19,999


INTRAOPERATIVE DATA COLLECTION FOR THE USE OF A NOVEL DIGITAL FLUOROSCOPIC GRID

OrthoGrid Technologies



CRV_00074880 Rock HadleyAssistant Professor and Co‐Investigator

Evaluation of Research Hardware and Software to Improve Magnetic Resonance (MR) Imaging and Spectroscopy with Human Subjects #N/A Intellectual Property


CRV_00074890 Mark Jensen Student and Co‐InvestigatorThe Hemocompatibility Study of Silica Nanoparticles as a function of Size and Surface Properties N/A Intellectual Property


CRV_00074906 Mark Yandell Professor and Co‐Investigator Endometriosis: Natural History, Diagnosis, and Outcomes (ENDO) Fabric Genomics


CRV_00074911 Mark Yandell Professor and Co‐Investigator Familial kinship analysis in patients with Mullerian anomalies Fabric Genomics


CRV_00074950 Edward Gilbert Professor and Co‐InvestigatorMOMENTUM 3 Multi‐Center Study of MagLev Technology in Patients Undergoing MCS Therapy with HeartMate 3

Abbott Laboratories Research (non‐OSP) $40,000‐59,999

CRV_00074968 Feng Liu Professor and Principal Investigator Testing lifeE's samples of electrothermal coating LIFE‐E Equity Interest $5,000‐9,999


Sanofi TCD14079>>A Phase 1b Study of SAR650984 (isatuximab) in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma SAR650984 / TCD14079) Celgene


CRV_00075164 Jonathan TwardAssociate Professor and Principal Investigator

A Retrospective Study of Prolaris for the Prediction of Progression in Men Treated with Modern External Beam Radia on Therapy for Prostate Cancer

Myriad Genetics Income for Consulting $5,000‐9,999

CRV_00075233 James HotalingAssistant Professor and Co‐Investigator SPERM SAMPLE PREPARATION FOR POINT OF CARE APPLICATIONS NanoNC Equity Interest <$5,000

CRV_00075234 Bruce Gale Professor and Principal Investigator SPERM SAMPLE PREPARATION FOR POINT OF CARE APPLICATIONS NanoNC Equity Interest $40,000‐59,999

CRV_00075308 Peter Stevens Professor and Co‐Investigator Growth Modulation in Achondroplasia N/ARoyalty Income from Intellectual Property >$100,000

CRV_00075529 Swomitra MohantyAssociate Professor and Principal Investigator

EVALUATION OF A NOVEL BREATH SENSOR FOR RAPID, LOW‐COST DIAGNOSIS OF TUBERCULOSIS IN CHILDREN N/A Intellectual Property


CRV_00075563 Philip BernardAssociate Professor and Co‐Investigator GENETIC EPIDEMIOLOGY OF BREAST CANCER Bioclassifier




TARGETING COLLAGEN MECHANICAL DAMAGE USING COLLAGEN HYBRIDIZING PEPTIDES 3Helix



CRV_00075641 Martin McMahon Professor and Principal InvestigatorELUCIDATING TUMOR PROGRESSION FACTORS IN MAPK‐DRIVEN LUNG CANCERS #N/A Intellectual Property $10,000‐19,999

CRV_00075828 Robert Tashjian Professor and Co‐InvestigatorOptimal Treatment of Glenoid Retroversion in Shoulder Arthroplasty

Wright Medical Technology

Income for Consulting/Equity Interest $80,000‐$99,999

CRV_00075882 Mark Yandell Professor and Co‐Investigator A Feasibility Study for the Early Detection of Pancreatic Cancer Fabric Genomics



Prospective Study on Embolization of Intracranial Aneurysms with Pipeline Embolization Device (PREMIER) Covidien Income for Consulting $40,000‐59,999

CRV_00076181 Tim JenkinsAssociate Professor and Principal Investigator SPERM SAMPLE PREPARATION FOR POINT OF CARE APPLICATIONS NanoNC



A Phase 3, Multi‐Center Open ‐Label, Randomized Study of Oral ABL001 versus Bosutinib in Patients with Chronic Myelogenous Leukemia in chronic phase (CML‐CP), Previously Treated with 2 or more Tyorsine Kinase Inhibitors. Pfizer


CRV_00076219 Michael Deininger Professor and Principal Investigator Stopping Tyrosine Kinase Inhibitors in CML Patients Pfizer


CRV_00076232 Michael Deininger Professor and Principal Investigator STOPPING TYROSINE KINASE INHIBITORS IN CML PATIENTS Pfizer





Therapeutic Drug Monitoring of Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibotor Therapy uing Scalp Hair Concentrations Pfizer




CRV_00076276 Michael Deininger Professor and Principal Investigator Medical College of Wisconsin>>The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST study) Pfizer



THERAPEUTIC DRUG MONITORING OF CHRONIC MYELOID LEUKEMIA PATIENTS ON TYROSINE KINASE INHIBITOR THERAPY USING SCALP HAIR CONCENTRATIONS Pfizer



Pfizer AV001>>A Multicenter Phase 3, Randomized, Open‐Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Pfizer



Novartis CABL001A2301>>A Phase 3, Multi‐Center, Open‐Label, Randomized Study Of Oral ABL001 Versus Bosutinib In Patients With Chronic Myelogenous Leukemia In Chronic Phase (CML‐CP), Previously Treated With 2 Or More Tyrosine Kinase Inhibitors

Pfizer


CRV_00076322 Gerald Krueger Professor and Co‐Investigator ABBVIE PSORIASIS RESEARCH FELLOWSHIP Abbvie



I1F‐MC‐RHCD ‐ Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab, in Patients from 6 to Less than 18 Years of Age with Moderate‐to‐Severe Plaque Psoriasis Eli Lilly



M16‐766 ‐ A Multicenter, Randomized, Open Label, Efficacy Assessor‐Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis who are Candidates for Systemic Therapy Abbvie


CRV_00077011 ALAN MORRIS Professor and Co‐Investigator University of Utah Atrial Fibrillation Database: AFIB Marrek, Inc Equity InterestValue cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00077016 Douglas Carrell Professor and Principal Investigator SPERM SAMPLE PREPARATION FOR POINT OF CARE APPLICATIONS NanoNC

Equity Interest/Intellectual Property <$5,000


I4V‐MC‐JAIX ‐ A Multicenter, Open‐Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis Eli Lilly


CRV_00077276 Karen Eilbeck Professor and Co‐Investigator

Utah Markers of Risk: Endometriosis (MORENDO) A Longitudinal Sample Collec on Study

IDbyDNA



Utah Markers of Risk: Endometriosis (MORENDO) A Longitudinal Sample Collec on Study

IDbyDNA


CRV_00077398 Robert SchlabergAssistant Professor and Co‐Investigator

METAGENOMICS APPROACH TO THE EVALUATION OF KAWASAKI DISEASE: A MULTICENTER PILOT STUDY IDbyDNA

Income for Consulting/Advisory Board/Equity Interest/Intellectual Property $60,000‐79.999

CRV_00077671 Jared ThorleyNurse Practitioner and Co‐Investigator

Exelixis XL184‐021>>A Phase 1b Dose‐Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors Exelixis Income for Speaking $10,000‐19,999

CRV_00077672 Julia BattenNurse Practitioner and Co‐Investigator

Exelixis XL184‐021>>A Phase 1b Dose‐Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors Exelixis Income for Speaking $10,000‐19,999

CRV_00077677 Robert Tashjian Professor and Co‐Investigator Kator Anchor Performance Evaluation for Rotator Cuff Repair KATOR Equity Interest $40,000‐59,999CRV_00077748 Robert Burks Professor and Co‐Investigator Kator Anchor Performance Evaluation for Rotator Cuff Repair KATOR Equity Interest <$5,000

CRV_00077846 Jared ThorleyNurse Practitioner and Co‐Investigator

Cabozantinib plus Pembrolizumab as First‐Line Therapy for Cisplatin‐Ineligible Advanced Urothelial Carcinoma (PemCab) Exelixis Income for Speaking $10,000‐19,999

CRV_00077847 Julia BattenNurse Practitioner and Co‐Investigator

Cabozantinib plus Pembrolizumab as First‐Line Therapy for Cisplatin‐Ineligible Advanced Urothelial Carcinoma (PemCab) Exelixis Income for Speaking $10,000‐19,999


Merck MK‐3475‐185>> A phase III study of Lenalidomide and low‐dose Dexamethasone with or without Pembrolizumab (MK3475) in newly diagnosed and treatment naïve Multiple Myeloma (KEYNOTE 185).

Celgene


CRV_00078474MARY KAY HARPER‐IRELAND Research Staff and Co‐Investigator

EXPLORING THE CHEMISTRY OF MARINE INVERTEBRATE ORGANISMS FOR DRUG DISCOVERY AND CHEMOTAXONOMY Sirenas Income for Consulting $10,000‐19,999

coi other public disclosures 2017 managed · crv_00006569 carl thummel professor and principal...

Documents